<DOC>
	<DOCNO>NCT01801046</DOCNO>
	<brief_summary>This phase I trial study side effect donor stem cell transplant treating patient high risk acute myeloid leukemia . Giving low dos chemotherapy donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell exactly match patient 's blood . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect )</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With High Risk Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess feasibility cytarabine base chemotherapy human leukocyte antigen ( HLA ) -mismatched allogeneic cellular therapy ( HMMACT ) patient high risk acute myeloid leukemia ( AML ) , feasibility measure induction mortality ( IM ) complete response rate . SECONDARY OBJECTIVES : I . To obtain preliminary estimate clinical outcome follow cytarabine base chemotherapy HMMACT patient high risk AML , measure event free survival ( EFS ) overall survival ( OS ) . II . To evaluate safety outcome induction consolidation cytarabine HMMACT term serious infection ( grade 4 ) , time recovery absolute neutrophil count platelet incidence graft versus host disease ( GvHD ) . III . To evaluate feasibility approach term identify suitable donor elderly population . IV . To compare preliminary manner clinical outcome cytarabine HMMACT patient high risk AML measure complete response rate ( CRR ) , event free survival ( EFS ) overall survival ( OS ) donor/recipient HLA-C1 v C2 pair . V. To characterize preliminary manner , number suppressor regulatory T cell ( Tregs ) , T helper 17 cell ( Th17 ) , cytotoxic T cell pre post HMMACT treatment , clinical outcome leukemia . OUTLINE : INDUCTION CHEMOTHERAPY : Patients receive mitoxantrone hydrochloride intravenously ( IV ) day 1-3 cytarabine IV day 1-7 . HMMACT : Patients receive filgrastim ( G-CSF ) mobilize peripheral blood stem cell ( G-PBSC ) day 9 . After completion study treatment , patient follow monthly 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Patients must histologically cytological confirm acute myeloid leukemia , high risk AML define : Age &gt; 60 , Presence complex cytogenetic abnormality ( &gt; 3 cytogenetic abnormality ) , del ( 7q , 5 , 7 ) , ( 9,22 ) , 11q ( 23 ) high risk mutation FISH eg MLL , FLT3 + Secondary AML , A white blood cell count &gt; 50 x10^9/L Patients must medically ineligible allogeneic stem cell transplant ( alloSCTx ) know fully HLA match sibling plan sibling transplant . Patients must measurable evaluable disease Diagnosis AML accord World Health Organization ( WHO ) diagnostic criterion ( least 20 % blast peripheral blood bone marrow ) , FrenchAmericanBritish Cooperative group ( FAB ) classification M3 ( acute promyelocytic leukemia ) , document bone marrow aspiration biopsy perform within 14 day prior administration 1st dose remission induction chemotherapy ; bone marrow aspirate biopsy obtain within 28 day prior first dose remission induction therapy test may submit review University Southern California ( USC ) repeat screen bone marrow need conduct ; Cohort A : newly diagnose AML , prior cytotoxic chemotherapy Cohort B : newly diagnose AML , fail achieve Complete remission ( CR ) single standard Induction chemo . Patient least one medically fit family member expect HLA mismatch 19/10 ; commonly prefer : 46/10 locus ( parent , sibling , niece/nephew , etc adult child prefer ) Absolute neutrophil count ( ANC ) &gt; 1500 , unless due direct bone marrow involvement disease Platelets &gt; 75,000 , unless due direct bone marrow involvement disease Hemoglobin &gt; 8.0 gm/dL , transfusion allow Serum creatinine &lt; 2.0 x upper limit institutional normal ( ULN ) Total bilirubin &lt; 1.5 x upper limit institutional normal Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &lt; 2.5 x upper limit institutional normal ( = &lt; 5 x ULN patient liver involvement leukemia ) Cardiac leave ventricular ejection fraction ( LVEF ) &gt; 45 % Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Estimated survival least 3 month Patients must able understand agree sign Institutional Review Board ( IRB ) approve informed consent form Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry , duration study , two month study participation DONOR : Donor screening ; donor meet standard blood donor criterion establish participate local blood center , American Association Blood Banks ( AABB ) DONOR : Donors select among subject 's relative , adult child prefer DONOR : Infectious disease test do per Hemacare policy AAAB guideline DONOR : Donor intend recipient red cell type compatibility determine DONOR : Donors preselected basis HLA haploidentity DONOR : If patient cytomegalovirus ( CMV ) negative , donor CMVnegative prefer ; CMV serology donor test prior allogeneic cell donation ; donation CMVpositive donor CMVnegative recipient give CMV negative donor available , CMV surveillance preemptive treatment give Cohort A : Patients receive prior cytotoxic chemotherapy , anthracyclines cytarabine permit ; prior treatment demethylating agent ( azacytidine decitabine , lenalidomide , etc ) ALLOWED . Cohort B : Patients receive prior fludarabine , clorarabine drug know target T cell permit ; prior standard induction anthracylines cytarabine ALLOWED include demethylating agent . Have uncontrolled systemic infection , coagulation disorder , major medical illness cardiovascular respiratory system Pregnant and/or lactate Patients nonbiopsy surgery last 10 day Active central nervous system ( CNS ) disease ; patient previously treat leptomeningeal disease without evidence remain leukemia cell spinal fluid eligible Known active autoimmune disorder Known human immunodeficiency virus ( HIV ) positive active hepatitis B C Patients concurrently take follow drug exclude : mycophenolate , cyclosporine , prednisone &gt; 20mg/day , immunosuppressive agent DONOR : Personal family history severe sickle cell disease variant ( unless donor test negative ) ; test presence hemoglobin S require DONOR : Positive infectious disease test dictate blood collection center 's standard operating procedure ( SOP ) DONOR : Current uncontrolled hypertension DONOR : Diabetes mellitus DONOR : Active peptic ulcer disease DONOR : Pregnant breastfeed DONOR : Currently take lithium therapy DONOR : History autoimmune disease DONOR : History coronary disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>